CTLA4 and metastatic melanoma: Earlier work has identified peripheral immune cell populations such as MDSCs or effector T-cell phenotypes as promising biomarker candidates for the clinical outcome of anti-CTLA4 checkpoint blockade in metastatic melanoma[8–10].